Evaluation of Upper Esophageal Sphincter Motor Activity in Patients with Extra Esophageal Reflux Symptoms
NCT ID: NCT06773702
Last Updated: 2025-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
50 participants
OBSERVATIONAL
2020-03-20
2025-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of HRM Score for the GERD Diagnosis
NCT05851482
High Resolution Manometry After Partial Fundoplication for Gastro-oesophageal Reflux
NCT05132816
Diagnostic Evaluation of Esophageal Motility Disorders Using the Chicago IV Protocol in Egypt
NCT06878586
Foreshortened Esophagus and Its Surgical Therapy
NCT00507377
Structure and Function of the Gastro-esophageal Junction
NCT01053585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
According to the 2006 Montreal classification (Figure 1), still the reference of gastroesophageal reflux disease, the disease can manifest with:
1. esophageal syndrome, subdivided into:
* symptomatic, without esophageal injury (typical reflux syndrome, Chest pain syndrome)
* syndrome with esophageal damage (esophagitis, stenosis, Barrett's esophagus and Adenocarcinoma of the esophagus)
2. extraesophageal syndrome, subdivided into:
* association with established reflux disease (chronic cough, laryngitis, asthma, dental erosions)
* association with proposed reflux disease (pharyngitis, sinusitis, idiopathic pulmonary fibrosis, recurrent otitis media).
A study performed by Francis DO in the United States in 2013 showed how the management of extra esophageal reflux disease substantially burdens public spending. In fact, it was found that the cost for the first year of evaluation and treatment of patients presenting with extra esophageal reflux symptoms is five times higher than the management of typical esophageal reflux disease. The cause of this discrepancy is precisely the absence of a definitive diagnosis and standard treatment, which result in difficult management of the disease.
While there is ample literature regarding the association between MRGE and alteration of the lower esophageal sphincter, little is described about the correlation between alterations in pharyngo-laryngeal motor activity and the upper esophageal sphincter in patients with extraesophageal reflux disease symptoms.
Indeed, it is hypothesized that the reflux of acidic material at the level of the larynx may be due to a dysfunction of the sphincter that acts as an escape valve between the esophagus and pharyngo-larynx. With the development of high-resolution manometry, which, unlike conventional manometry, has no spatial gaps and allows for a faithful representation of esophageal motor function in time and space, a detailed study of oropharyngeal and upper esophageal sphincter motor activity can be achieved
The observational, non-interventional nature of the study is based on two main elements:
1. the evaluation of data obtained from high-resolution esophageal manometry in patients with extra-esophageal reflux symptoms
2. the comparison of data obtained from high-resolution esophageal manometry with 24-hour PH-impedancemetry and otolaryngological scores of laryngopharyngeal reflux (Reflux symptom Index, Reflux Finding Score) Patients participating in the study will not undergo any procedures beyond normal daily clinical practice; likewise, the clinical variables that will be collected for the study are those that are commonly collected by the physician in daily clinical practice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with laryngopharyngeal reflux symptoms
Gastroenterological evaluation by esophageal manometry, 24-hour Ph impedance testing, Otolaryngological evaluation by laryngoscopy
gastroenterology and otolaryngological evaluation
* Gastroenterology evaluation: presence and intensity of esophageal symptoms of gastro esophageal reflux disease, high-resolution esophageal manometry, and 24-hour pH-impedancometry in the absence of PPI therapy.
* otolaryngological evaluation: presence and intensity of laryngopharyngeal reflux symptoms, laryngoscopy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gastroenterology and otolaryngological evaluation
* Gastroenterology evaluation: presence and intensity of esophageal symptoms of gastro esophageal reflux disease, high-resolution esophageal manometry, and 24-hour pH-impedancometry in the absence of PPI therapy.
* otolaryngological evaluation: presence and intensity of laryngopharyngeal reflux symptoms, laryngoscopy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with laryngopharyngeal reflux symptoms.
Exclusion Criteria
* Patients with occupational exposure to irritants (artisans and industrial workers).
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesco Torresan, MD
Role: PRINCIPAL_INVESTIGATOR
IRCCS AOUBo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VAM-SES-SEER2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.